View Financial HealthLuye Pharma Group 배당 및 자사주 매입배당 기준 점검 0/6Luye Pharma Group 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesLuye Pharma Group Ltd., Annual General Meeting, Jun 26, 2026Mar 31Luye Pharma Group Ltd. to Report Fiscal Year 2025 Results on Mar 30, 2026Mar 17Luye Pharma Group Ltd. Announces New Drug Application for Class 1 Innovative Drug Ruoxinlin for the New Indication of Generalized Anxiety DisorderJan 08Luye Pharma Group Ltd. Appoints Ms. Xia Lian as A Member of the Nomination Committee, with Effect from 31 December 2025Jan 02Luye Pharma Group Ltd. to Report First Half, 2025 Results on Aug 28, 2025Aug 18+ 1 more updateLuye Pharma Group Ltd. Announces Class 1 Innovative Antidepressant Ruoxinlin® Approved for Marketing in MacaoApr 10Luye Pharma Group Announces U.S. Launch of Erzofri (Paliperidone Palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective DisorderApr 07Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer's DementiaApr 03Luye Pharma Group Ltd., Annual General Meeting, May 28, 2025Mar 31Luye Pharma Group Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Mar 14Luye Pharma Group Ltd. Announces Change of Non-Executive DirectorMar 10Luye Pharma Group Ltd. Announces Approval for the Group's New Drug LY03020 for Clinical Trials in the U.SJan 16+ 1 more updateLuye Pharma Group Ltd. Announces Approval of Zepzelca (Lurbinectedin for Injection) for Marketing in Mainland ChinaDec 03First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023) Oct 02First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023) Aug 30Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024Aug 15Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective DisorderJul 29Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion.Jul 24Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in ChinaJul 04Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in ChinaJun 13Full year 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.17 in FY 2022) Mar 28Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024Mar 28Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024Mar 15Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and MacaoMar 09Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610Mar 04Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United StatesFeb 02Now 21% undervalued after recent price drop Jan 24Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong KongDec 12Luye Pharma Group Ltd. Announces Board ChangesDec 06Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective DisorderOct 11First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022) Oct 01Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products AdministratioSep 09First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022) Aug 31Luye Pharma Group Ltd. Submits New Drug Application for LurbinectedinAug 22Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United StatesAug 18+ 1 more updateLuye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in ChinaJul 07Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation TherapyJul 06Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in UzbekistanJun 09Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in ChinaJun 08Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive DirectorMay 26Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.039 loss in FY 2021) Mar 30Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022)Jan 31FDA Approves Luye Pharma's Rykindo for the Treatment of Schizophrenia and Bipolar 1 DisorderJan 16Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010)Dec 29Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014Nov 30Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product CandidateNov 22Less than half of directors are independent Nov 16Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPANov 04Luye Pharma Group Ltd. announced that it expects to receive CNY 300 million in fundingSep 15First half 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.11 in 1H 2021) Aug 31Luye Pharma Group Ltd. to Report Q2, 2022 Results on Aug 29, 2022Aug 18Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in ChinaAug 16Luye Pharma Group Ltd. Announces Phase III Clinical Trial of RotigotineJul 20Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in HainanJul 19Luye Pharma Group Ltd. Announces Dulaglutide Injection BA5101 Entered into Phase III Clinical Trial in ChinaJul 15Luye Pharma Group Ltd. Announces Results of A Phase III Clinical Trial of Class 1 New Drug Ly03005 Presented At the 2022 APA Annual MeetingJun 09Luye Pharma Group Ltd. Announces Results of A Phase I Clinical Trial of Lurbinectedin as Second-Line Therapy in Chinese Patients with SCLC Presented At the 2022 Asco Annual MeetingJun 07Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022May 18Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial for Class 1 New Drug LY03014 in ChinaMay 12Full year 2021 earnings released: CN¥0.039 loss per share (vs CN¥0.22 profit in FY 2020) May 01Less than half of directors are independent Apr 27Full year 2021 earnings released: CN¥0.039 loss per share (vs CN¥0.22 profit in FY 2020) Mar 31Luye Pharma Group Ltd. Submits a New Drug Application for Lurbinectedin (LY01017) for InjectionMar 06Luye Pharma Group Ltd. Announces New Indications Approved for Boyounuo® (Bevacizumab Injection) in ChinaFeb 26Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trials for Monthly Microsphere Injection New Drug LY03009 for Parkinson's Disease in the United StatesJan 20Luye Pharma Group Ltd. Announces Acceptance of Application for Marketing Authorization in China for Goserelin Acetate Extended-Release Microspheres for Injection (LY01005)Dec 30Luye Pharma Group Releases Top-Line Results from A Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release TabletsDec 23Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for Group\U0027s Innovative Antibody Drug BA1201 in ChinaDec 15First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020) Oct 01Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Dulaglutide Injection (BA5101) in ChinaSep 29Luye Pharma Group Ltd.'s New Drug Rivastigmine Multi-Day Transdermal Patch Receives Marketing Authorization from the Medicines & Healthcare Products Regulatory Agency in the United KingdomSep 24Luye Pharma Becomes the Marketing Authorization Holder for Seroquel and Seroquel XR in Saudi ArabiaSep 20First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020) Sep 01Luye Pharma Group Ltd. Announces Clinical Trial Application Submitted in the U.S. for the Group's U0027s New Drug LY03015Aug 04Shandong Boan Biotechnology Co. Ltd. Submits Investigational New Drug Application for Its New Drug LY-CovMab to the Food and Drug Administration of the U.SJun 16Luye Pharma Group Ltd. Announces Acceptance of Marketing Authorization Application for Class 1 New Drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) in ChinaJun 11Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for its New Drug LY09606 in ChinaMay 14Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Nivolumab Injection in ChinaMay 07+ 1 more updateFull year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.44 in FY 2019) May 03Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.46 in FY 2019) Apr 04Luye Pharma Group Ltd. Announces Enrolment of Subjects in Phase I Clinical Trial in the People's Republic of China Commenced in Relation to the Group's Class 1 New Drug LPM3480392 InjectionMar 19Luye Pharma Group Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021Mar 17Centre for Drug Evaluation of the National Medical Products Administration in the People's Republic of China Accepts Luye Pharma Group Ltd.'s Application for its New Drug LY09606Mar 09Luye Pharma Group Ltd. Announces Recombinant Human Vascular Endothelial Growth Factor Receptor Antibody Fusion Protein Ophthalmic Injection of Shandong Boan Biotechnology Co. Ltd. Completes the First Patient Dosing in Phase III Clinical Trial in ChinaFeb 09+ 2 more updatesNew 90-day high: €0.58 Feb 02Luye Pharma Group Ltd. Announces Completion of Enrollment of Subjects in Phase I Clinical Trial for Neutralizing Antibody Against SARS-CoV--2 in ChinaJan 20Luye Pharma Group Ltd. Announces Marketing Registration of Risperidone Microspheres for Injection Approved by NMPAJan 17Luye Pharma Group Ltd. Announces Rotigotine Extended-Release Microspheres for Injection (Ly03003) Completed Phase I Clinical Trial in JapanJan 16Luye Pharma Group Ltd. Updates on LY03009 Commenced Phase I Clinical Trial in AustraliaJan 06New 90-day low: €0.34 Dec 30Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial of Class 1 New Drug Product, the Extended Release TabletsDec 25Luye Pharma Group Ltd. Announces Commencement of LY03010 Pivotal Study in the U.SDec 23New 90-day low: €0.41 Dec 11Luye Pharma Group Ltd. Announces Executive ChangesDec 02지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 LUP 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: LUP 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Luye Pharma Group 배당 수익률 vs 시장LUP의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (LUP)0%시장 하위 25% (DE)1.6%시장 상위 25% (DE)4.5%업계 평균 (Pharmaceuticals)2.8%분석가 예측 (LUP) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 LUP 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 LUP 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: LUP German 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: LUP 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 21:40종가2026/04/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Luye Pharma Group Ltd.는 17명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jessica LiBofA Global ResearchLok Kwan ChiuCCB International Securities LimitedLing ZhangChina Merchants Securities (HK) Co., Ltd14명의 분석가 더 보기
Luye Pharma Group Ltd. Announces New Drug Application for Class 1 Innovative Drug Ruoxinlin for the New Indication of Generalized Anxiety DisorderJan 08
Luye Pharma Group Ltd. Appoints Ms. Xia Lian as A Member of the Nomination Committee, with Effect from 31 December 2025Jan 02
Luye Pharma Group Ltd. Announces Class 1 Innovative Antidepressant Ruoxinlin® Approved for Marketing in MacaoApr 10
Luye Pharma Group Announces U.S. Launch of Erzofri (Paliperidone Palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective DisorderApr 07
Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer's DementiaApr 03
Luye Pharma Group Ltd. Announces Approval for the Group's New Drug LY03020 for Clinical Trials in the U.SJan 16+ 1 more update
Luye Pharma Group Ltd. Announces Approval of Zepzelca (Lurbinectedin for Injection) for Marketing in Mainland ChinaDec 03
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective DisorderJul 29
Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion.Jul 24
Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in ChinaJul 04
Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in ChinaJun 13
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and MacaoMar 09
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610Mar 04
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United StatesFeb 02
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong KongDec 12
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective DisorderOct 11
Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products AdministratioSep 09
Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United StatesAug 18+ 1 more update
Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in ChinaJul 07
Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation TherapyJul 06
Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022)Jan 31
Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010)Dec 29
Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014Nov 30
Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product CandidateNov 22
Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPANov 04
Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in ChinaAug 16
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in HainanJul 19
Luye Pharma Group Ltd. Announces Dulaglutide Injection BA5101 Entered into Phase III Clinical Trial in ChinaJul 15
Luye Pharma Group Ltd. Announces Results of A Phase III Clinical Trial of Class 1 New Drug Ly03005 Presented At the 2022 APA Annual MeetingJun 09
Luye Pharma Group Ltd. Announces Results of A Phase I Clinical Trial of Lurbinectedin as Second-Line Therapy in Chinese Patients with SCLC Presented At the 2022 Asco Annual MeetingJun 07
Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial for Class 1 New Drug LY03014 in ChinaMay 12
Luye Pharma Group Ltd. Submits a New Drug Application for Lurbinectedin (LY01017) for InjectionMar 06
Luye Pharma Group Ltd. Announces New Indications Approved for Boyounuo® (Bevacizumab Injection) in ChinaFeb 26
Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trials for Monthly Microsphere Injection New Drug LY03009 for Parkinson's Disease in the United StatesJan 20
Luye Pharma Group Ltd. Announces Acceptance of Application for Marketing Authorization in China for Goserelin Acetate Extended-Release Microspheres for Injection (LY01005)Dec 30
Luye Pharma Group Releases Top-Line Results from A Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release TabletsDec 23
Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for Group\U0027s Innovative Antibody Drug BA1201 in ChinaDec 15
Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Dulaglutide Injection (BA5101) in ChinaSep 29
Luye Pharma Group Ltd.'s New Drug Rivastigmine Multi-Day Transdermal Patch Receives Marketing Authorization from the Medicines & Healthcare Products Regulatory Agency in the United KingdomSep 24
Luye Pharma Becomes the Marketing Authorization Holder for Seroquel and Seroquel XR in Saudi ArabiaSep 20
Luye Pharma Group Ltd. Announces Clinical Trial Application Submitted in the U.S. for the Group's U0027s New Drug LY03015Aug 04
Shandong Boan Biotechnology Co. Ltd. Submits Investigational New Drug Application for Its New Drug LY-CovMab to the Food and Drug Administration of the U.SJun 16
Luye Pharma Group Ltd. Announces Acceptance of Marketing Authorization Application for Class 1 New Drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) in ChinaJun 11
Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for its New Drug LY09606 in ChinaMay 14
Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Nivolumab Injection in ChinaMay 07+ 1 more update
Luye Pharma Group Ltd. Announces Enrolment of Subjects in Phase I Clinical Trial in the People's Republic of China Commenced in Relation to the Group's Class 1 New Drug LPM3480392 InjectionMar 19
Centre for Drug Evaluation of the National Medical Products Administration in the People's Republic of China Accepts Luye Pharma Group Ltd.'s Application for its New Drug LY09606Mar 09
Luye Pharma Group Ltd. Announces Recombinant Human Vascular Endothelial Growth Factor Receptor Antibody Fusion Protein Ophthalmic Injection of Shandong Boan Biotechnology Co. Ltd. Completes the First Patient Dosing in Phase III Clinical Trial in ChinaFeb 09+ 2 more updates
Luye Pharma Group Ltd. Announces Completion of Enrollment of Subjects in Phase I Clinical Trial for Neutralizing Antibody Against SARS-CoV--2 in ChinaJan 20
Luye Pharma Group Ltd. Announces Marketing Registration of Risperidone Microspheres for Injection Approved by NMPAJan 17
Luye Pharma Group Ltd. Announces Rotigotine Extended-Release Microspheres for Injection (Ly03003) Completed Phase I Clinical Trial in JapanJan 16
Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial of Class 1 New Drug Product, the Extended Release TabletsDec 25